RT Journal Article
SR Electronic
T1 409 Development of<em>
<em>ex vivo</em>
</em> precision gene engineered B cell medicines that produce highly active and sustained levels of transgenic anti-tumor biologics
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A458
OP A458
DO 10.1136/jitc-2023-SITC2023.0409
VO 11
IS Suppl 1
A1 Edelstein, Jasmine N
A1 Hill, Tyler F
A1 Leiken, Michael D
A1 Molloy, Katherine M
A1 Adekanye, Glory
A1 Bullock, Caroline
A1 Lazorchak, Adam S
A1 Aryee, Ken-Edwin
A1 Rawlings, David J
A1 James, Richard G
A1 Morgan, Richard A
A1 Arlauckas, Sean P
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A458.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.